Evaluating the use of long-acting antiretroviral treatment for HIV during community re-entry: Addressing community and structural barriers
Evaluating the use of long-acting antiretroviral treatment for HIV during community re-entry: Addressing community and structural barriers
批准号:
10818986
负责人:
GEORGIA Doris TOMARAS
金额:
$50.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
未结题
起止时间:
2005-04-01 至 2025-06-30
关键词:
AddressAdherenceAdministratorAreaBackBaltimoreCommunitiesCommunity Health AidesCommunity ServicesConsolidated Framework for Implementation ResearchCountyDataDelphi StudyDevelopmentEmploymentEnvironmentEpidemicFDA approvedFoundationsFundingFutureGeographic LocationsGuidelinesHIVHIV InfectionsHealthHealth InsuranceHealth ServicesHealth Services AccessibilityHousingImprisonmentIndividualInjectableInterventionInterviewIntramuscular InjectionsInvestigationJusticeLocationLogicMapsMedical StaffMedicineMental HealthMental disordersMethodologyMethodsMid-Atlantic RegionModalityModelingOralPatientsPersonsPharmaceutical PreparationsPopulationPositioning AttributePovertyPractice GuidelinesProcessProtocols documentationProviderPublic HealthRandomized, Controlled TrialsRegimenRelapseResearchResearch SupportRiskSeriesServicesSiteSocial SciencesSubstance Use DisorderSurveysTheoretical modelTimeTrainingTreatment outcomeUnemploymentUnited StatesVulnerable PopulationsWalkingWashingtonWorkantiretroviral therapycommunity reentrydesignexperiencehigh risk populationhousing instabilityimplementation researchimplementation scienceimprovedinnovationopioid use disorderpeerpilot testpoor health outcomeservice providerssocialsubstance useviral rebound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Persons who experience incarceration are disproportionately impacted by HIV infection. The time of release from
carceral settings, known as community re-entry, is a period of particularly high risk for persons with HIV. During
this time, people are at an increased risk of viral rebound due to poor ART adherence, substance use relapse,
inability to engage with community HIV providers, inability to fill ART prescriptions, and competing needs in the
chaotic environment to which individuals return. Long-acting injectable (LAI) ART is a new alternative to help
overcome the challenges of adhering to a daily regimen of oral medication. However, little is known about how
best to develop and optimize LAI ART interventions in this population. Therefore, we propose exploratory
implementation research that will provide additional preliminary data to enhance our understanding of LAI ART
implementation in diverse Ending the HIV Epidemic (EHE) areas in the mid-Atlantic region: Prince Georges
County, MD; and Washington, DC. Using the Consolidated Framework for Implementation Research—a
theoretical model that guides investigation into the factors that influence implementation, we propose
interviewing stakeholders in each of the above EHE areas and conducting a Delphi study. Specific focus will be
placed on linkage to a broad array of health services (e.g., mental health, substance use, the need for peer or
community health worker services) and the structural barriers that might be present in each location (health
insurance, housing, employment, poverty). Our specific aims are to: 1) identify how to optimize future LAI ART
interventions in community re-entry populations by interviewing 15 stakeholders at each site (total n=45), and 2)
co-produce best practice guidelines for future LAI ART interventions by conducting a Delphi study with 30
experts. The proposed project maps onto the objectives of the funding announcement in that we will conduct
implementation research to develop a LAI intervention that addresses multi-level factors that are key to
facilitating linkage to innovative HIV treatment modalities. Findings from the supplement supported research will
be the foundation of a future R01 application and, importantly, will be shared back with our EHE implementation,
governmental, and community partners at each EHE site.
期刊论文(465)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3390/v13050852
发表时间:
2021-05-07
期刊:
Viruses
影响因子:
--
作者:
[Bennett AL, Henderson R]
通讯作者:
Henderson R
DOI:
10.3389/fimmu.2021.678511
发表时间:
2021
期刊:
Frontiers in immunology
影响因子:
7.3
作者:
[Pollara J, Tay MZ, Edwards RW, Goodman D, Crowley AR, Edwards RJ, Easterhoff D, Conley HE, Hoxie T, Gurley T, Jones C, Machiele E, Tuyishime M, Donahue E, Jha S, Spreng RL, Hope TJ, Wiehe K, He MM, Moody MA, Saunders KO, Ackerman ME, Ferrari G, Tomaras GD]
通讯作者:
Tomaras GD
DOI:
10.1080/17441692.2021.1951801
发表时间:
2022-12
期刊:
Global public health
影响因子:
3.3
作者:
[Schmidt CN, Puffer ES, Broverman S, Warren V, Green EP]
通讯作者:
Green EP
DOI:
10.1007/s10461-018-2289-9
发表时间:
2019-05
期刊:
AIDS and behavior
影响因子:
4.4
作者:
[Hightow-Weidman LB, LeGrand S, Muessig KE, Simmons RA, Soni K, Choi SK, Kirschke-Schwartz H, Egger JR]
通讯作者:
Egger JR
DOI:
10.1007/s10900-014-9979-7
发表时间:
2015-08
期刊:
JOURNAL OF COMMUNITY HEALTH
影响因子:
5.9
作者:
[Reif, Susan, Pence, Brian Wells, Hall, Irene, Hu, Xiaohong, Whetten, Kathryn, Wilson, Elena]
通讯作者:
Wilson, Elena
共 285 条
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ
-
批准号:10258146
-
项目类别:
-
资助金额:$434.33万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Mechanisms of Antibody Fc Mediated Protection
-
批准号:10475284
-
项目类别:
-
资助金额:$59.14万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:10670243
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Antiviral Activity In Situ
-
批准号:10475294
-
项目类别:
-
资助金额:$85.28万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ
-
批准号:10670229
-
项目类别:
-
资助金额:$444.84万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:10258147
-
项目类别:
-
资助金额:$33.21万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ
-
批准号:10475274
-
项目类别:
-
资助金额:$426.07万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Antiviral Activity In Situ
-
批准号:10670262
-
项目类别:
-
资助金额:$59.14万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Mechanisms of Antibody Fc Mediated Protection
-
批准号:10258150
-
项目类别:
-
资助金额:$60.67万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Structure-Function Analytics Core
-
批准号:10670249
-
项目类别:
-
资助金额:$100.92万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Structure-Function Analytics Core
-
批准号:10258149
-
项目类别:
-
资助金额:$76.49万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Structure-Function Analytics Core
-
批准号:10475280
-
项目类别:
-
资助金额:$73.44万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:10475275
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Mechanisms of Antibody Fc Mediated Protection
-
批准号:10670254
-
项目类别:
-
资助金额:$85.63万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Antiviral Activity In Situ
-
批准号:10258152
-
项目类别:
-
资助金额:$100.02万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
-
批准号:9925737
-
项目类别:
-
资助金额:$410.48万
-
财政年份:2016
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:9140248
-
项目类别:
-
资助金额:$14.72万
-
财政年份:2016
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
-
批准号:9140247
-
项目类别:
-
资助金额:$326.41万
-
财政年份:2016
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Centers for AIDS Research (CFAR)
-
批准号:10163778
-
项目类别:
-
资助金额:$330.19万
-
财政年份:2005
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Immunology Core (Basic Science Core)
-
批准号:10673776
-
项目类别:
-
资助金额:$15.15万
-
财政年份:2005
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
海外基金